Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Phocas Financial Corp.

Phocas Financial Corp. reduced its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 80.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,889 shares of the company’s stock after selling 813,301 shares during the period. Amneal Pharmaceuticals makes up 1.2% of Phocas Financial Corp.’s holdings, making the stock its 21st largest position. Phocas Financial Corp. owned approximately 0.07% of Amneal Pharmaceuticals worth $1,599,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Franklin Resources Inc. lifted its stake in shares of Amneal Pharmaceuticals by 4.9% during the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock worth $778,000 after buying an additional 4,178 shares during the period. Gladius Capital Management LP acquired a new position in shares of Amneal Pharmaceuticals in the third quarter valued at about $37,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Amneal Pharmaceuticals by 13.6% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company’s stock worth $366,000 after purchasing an additional 5,523 shares during the last quarter. Segall Bryant & Hamill LLC lifted its holdings in shares of Amneal Pharmaceuticals by 1.6% during the third quarter. Segall Bryant & Hamill LLC now owns 489,162 shares of the company’s stock worth $4,070,000 after purchasing an additional 7,661 shares during the period. Finally, Rhumbline Advisers boosted its position in Amneal Pharmaceuticals by 3.5% in the fourth quarter. Rhumbline Advisers now owns 232,264 shares of the company’s stock valued at $1,840,000 after buying an additional 7,875 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX opened at $8.50 on Wednesday. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $9.48. The company has a market cap of $2.63 billion, a PE ratio of -12.50 and a beta of 1.10. The stock’s 50 day simple moving average is $8.06 and its 200-day simple moving average is $8.31.

Wall Street Analyst Weigh In

Several analysts have commented on AMRX shares. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $9.00 to $12.00 in a research note on Monday. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Finally, Piper Sandler boosted their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $10.60.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $8.14, for a total transaction of $651,200.00. Following the transaction, the director now directly owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. The trade was a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold 160,000 shares of company stock valued at $1,292,000 over the last 90 days. 17.46% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.